UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity.

Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
The EMBO Journal (Impact Factor: 10.75). 07/2006; 25(11):2358-67. DOI: 10.1038/sj.emboj.7601149
Source: PubMed

ABSTRACT Interferons (IFNs) regulate diverse cellular functions through activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Lack of Ubp43, an IFN-inducible ISG15 deconjugating enzyme, leads to IFN hypersensitivity in ubp43-/- mice, suggesting an important function of Ubp43 in downregulation of IFN responses. Here, we show that Ubp43 negatively regulates IFN signaling independent of its isopeptidase activity towards ISG15. Ubp43 functions specifically for type I IFN signaling by downregulating the JAK-STAT pathway at the level of the IFN receptor. Using molecular, biochemical, and genetic approaches, we demonstrate that Ubp43 specifically binds to the IFNAR2 receptor subunit and inhibits the activity of receptor-associated JAK1 by blocking the interaction between JAK and the IFN receptor. These data implicate Ubp43 as a novel in vivo inhibitor of signal transduction pathways that are specifically triggered by type I IFN.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ubiquitin proteasome system (UPS) is the main system for controlled protein degradation and a key regulator of fundamental cellular processes. The dependency of cancer cells on a functioning UPS has made this an attractive target for development of drugs that show selectivity for tumor cells. Deubiquitinases (DUBs, ubiquitin isopeptidases) are components of the UPS that catalyze the removal of ubiquitin moieties from target proteins or polyubiquitin chains, resulting in altered signaling or changes in protein stability. A number of DUBs regulate processes associated with cell proliferation and apoptosis, and as such represent candidate targets for cancer therapeutics. The majority of DUBs are cysteine proteases and are likely to be more "druggable" than E3 ligases. Cysteine residues in the active sites of DUBs are expected to be reactive to various electrophiles. Various compounds containing α,β−unsaturated ketones have indeed been demonstrated to inhibit cellular DUB activity. Inhibition of proteasomal cysteine DUB enzymes (i.e. USP14 and UCHL5) can be predicted to be particularly cytotoxic to cancer cells as it leads to blocking of proteasome function and accumulation of proteasomal substrates. We here provide an overall review of DUBs relevant to cancer and of various small molecules which have been demonstrated to inhibit DUB activity.
    Pharmacology [?] Therapeutics 11/2014; 147. DOI:10.1016/j.pharmthera.2014.11.002 · 7.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ebola virus (EBOV) causes a severe hemorrhagic disease with high fatality. Virus-like particles (VLPs) are a promising vaccine candidate against EBOV. We recently showed that VLPs protect mice from lethal EBOV infection when given before or after viral infection. To elucidate pathways through which VLPs confer post-exposure protection, we investigated the role of type I interferon (IFN) signaling. We found that VLPs lead to accelerated induction of IFN stimulated genes (ISGs) in liver and spleen of wild type mice, but not in Ifnar-/- mice. Accordingly, EBOV infected Ifnar-/- mice, unlike wild type mice succumbed to death even after VLP treatment. The ISGs induced in wild type mice included anti-viral proteins and negative feedback factors known to restrict viral replication and excessive inflammatory responses. Importantly, proinflammatory cytokine/chemokine expression was much higher in WT mice without VLPs than mice treated with VLPs. In EBOV infected Ifnar-/- mice, however, uninhibited viral replication and elevated proinflammatory factor expression ensued, irrespective of VLP treatment, supporting the view that type I IFN signaling helps to limit viral replication and attenuate inflammatory responses. Further analyses showed that VLP protection requires the transcription factor, IRF8 known to amplify type I IFN signaling in dendritic cells and macrophages, the probable sites of initial EBOV infection. Together, this study indicates that VLPs afford post-exposure protection by promoting expeditious initiation of type I IFN signaling in the host.
    PLoS ONE 01/2015; 10(2):e0118345. DOI:10.1371/journal.pone.0118345 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the original properties attributed to this cytokine family, with schedules and modalities that reflect their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity, with the capacity to induce potent immune responses against foreign pathological agents. Physiologically, type I IFN is produced in large amounts by plasmacytoid dendritic cells and is rapidly silenced by self-regulatory mechanisms. The current schedule of treatment for infectious diseases, especially chronic hepatitis C, as well as for a limited number of hematological and solid tumors is based on the continuous administration of either intermediate or high dose recombinant or pegylated type I IFN, regardless of emerging data on the viral resistance, host genetic variants predicting treatment outcome and multiple mechanisms of refractoriness. New administration schedules, the combination of type I IFN with new drugs and increased monitoring of patients’ susceptibility are expected to provide a new life to this valuable cytokine.
    Cytokine & Growth Factor Reviews 12/2014; DOI:10.1016/j.cytogfr.2014.12.006 · 6.54 Impact Factor


Available from